All News
Filter News
Found 90 articles
-
Rivus raised $132 million in a Series B financing round that will be used in developing HU6, a new drug class designed to treat cardio-metabolic disease by addressing obesity.
-
Corbus Presents First Pre-Clinical Data for CRB-913 at the European Association for the Study of Diabetes 2022 Annual Conference
9/22/2022
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced that preclinical data for CRB-913 are being presented today in an oral presentation at the European Association for the Study of Diabetes 2022 Annual Conference taking place in Stockholm, Sweden.
-
Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/9/2022
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided a corporate update and reported financial results for the first quarter of 2022.
-
Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements
8/4/2022
Eli Lilly and Company announced its financial results for the second quarter of 2022.
-
The new chief executive officer of Versanis is going to push the obesity drug bimagrumab in the limelight against Novo and Lilly's drug. Here's all that you need to know.
-
As the calendar pages continue to turn, the FDA has a slew of novel drugs awaiting approval, several of which are likely to become game-changers for patients and key assets for companies.
-
The Phase I mechanism of action study, showing that Lilly's injectable Mounjaro (tirzepatide) induces greater weight loss than placebo and Novo Nordisk’s semaglutide in adults with type 2 diabetes.
-
New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions®
6/6/2022
New data from a mechanism of action study and new analyses of the global registration program for Eli Lilly and Company's (NYSE: LLY) Mounjaro™ (tirzepatide) injection were presented at the American Diabetes Association's® (ADA) 82nd Scientific Sessions®.
-
SURMOUNT-1 Study Finds Individuals with Obesity Lost up to 22.5% of their Body Weight when Taking Tirzepatide
6/4/2022
Findings from SURMOUNT-1, the first investigational phase 3 trial evaluating the safety and efficacy of tirzepatide for the treatment of obesity, were announced, representing a new class of medicines being studied for the treatment of obesity.
-
Tirzepatide Slowed Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes with Increased Cardiovascular Risk
6/3/2022
A pre-specified exploratory analysis from the SURPASS-4 trial showed tirzepatide, a novel once-weekly medication for the treatment of diabetes, improved kidney outcomes for adults with type 2 diabetes who have increased cardiovascular risk.
-
When the two new sites are up and running, Eli Lilly predicted the project will create up to 500 new jobs - with the expectation of four indirect jobs for each full-time position, based on industry data.
-
Phenomix Sciences Announces First Precision Obesity Biobanking Registry and Outcomes Study
5/25/2022
Phenomix Sciences, a precision obesity biotechnology company, announces the launch of its biobanking registry and outcomes study.
-
Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana
5/25/2022
Eli Lilly and Company (NYSE: LLY) plans to expand its manufacturing footprint in Indiana by investing $2.1 billion in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.
-
Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA
5/23/2022
Eli Lilly and Company (NYSE: LLY) will host a webcast on Tuesday, June 7, 2022 to discuss the company's diabetes and obesity portfolio and its presentations at the American Diabetes Association's 82nd Scientific Sessions.
-
In addition to lowering of blood sugar, Mounjaro also enabled patients to lower their weight by 15 to 23 pounds. The drug compared well to other diabetes medications including Novo Nordisk's semaglutide.
-
FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes
5/13/2022
Today, the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.
-
FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes
5/13/2022
The U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection, Eli Lilly and Company's (NYSE: LLY) new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
-
Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/10/2022
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided a corporate update and reported financial results for the first quarter of 2022.
-
Eli Lilly had a lucrative first quarter, with revenue growth rising 15% driven by sales of its diabetes drug Trulicity and its COVID-19 antibodies.
-
Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022
4/28/2022
Eli Lilly and Company announced its financial results for the first quarter of 2022.